Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report

• Published in: Journal of medical case reports Vol. 16; no. 1; p. 193
• Main Authors: Fuu, Takayoshi, Iijima, Kazuyoshi, Kusama, Yukiko, Otsuki, Toshiaki, Kato, Haruaki
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 18.05.2022; BioMed Central; BMC
• Subjects: Aged; B7-H1 Antigen; Bladder cancer; Cancer; Cancer therapies; Carcinoma; Carcinoma, Renal Cell - pathology; Carcinoma, Transitional Cell; Case Report; Case reports; Cell cycle; Chemotherapy; Collecting duct carcinoma; Combination therapy; Humans; Immune Checkpoint Inhibitors; Immune-related adverse events; Immunotherapy; Ipilimumab; Ipilimumab - therapeutic use; Kidney cancer; Kidney Neoplasms - drug therapy; Kidney Neoplasms - pathology; Kinases; Ligands; Liver cancer; Lymphatic system; Male; Medical imaging; Medical prognosis; Metastasis; Monoclonal antibodies; Neoplasms, Second Primary - drug therapy; Nivolumab - therapeutic use; Patients; Pneumonia; Prognosis; Programmed death-ligand 1; Response rates; Sarcoma; Sarcomatoid renal cell carcinoma; Soft Tissue Neoplasms - drug therapy; Targeted cancer therapy; Urinary Bladder Neoplasms - drug therapy; Case report; Immune checkpoint inhibitors; Immune-related adverse events; Collecting duct carcinoma; Programmed death-ligand 1; Sarcomatoid renal cell carcinoma

Collecting duct carcinoma and sarcomatoid renal cell carcinoma are tumors with poor prognosis. Immune checkpoint inhibitors have been established as the standard treatment for advanced renal cell carcinoma. Some cases of remission of collecting duct carcinoma and sarcomatoid renal cell carcinoma hav...